At the recent CTAD conference in Barcelona, Spain a number of companies presented new data regarding their Alzheimer’s drug candidates. Much of the attention focused on Biogen (BIIB), but other companies may be pursuing more fruitful strategies against Alzheimer’s disease. In many cases, results reflect the likely mechanisms of the disease whether its Biogen’s efforts to remove amyloid oligomers, Anavex’s (AVXL) focus on inhibiting intracellular calcium release, or Neurotrope’s (NTRP) hopes founded on the activation of protein kinase C. To a degree, each company’s efforts are linked to the chain